Anthem Biosciences Limited (BOM:544449)
India
· Delayed Price · Currency is INR 661.50
-1.25 (-0.19%)
At close: Dec 4, 2025
Anthem Biosciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Net Income | 5,162 | 4,513 | 3,673 | 3,852 | 4,055 | 2,713 |
| Depreciation & Amortization | 1,106 | 893.71 | 818.24 | 637.74 | 578.35 | 624.77 |
| Other Amortization | 0.39 | 0.78 | 0.78 | 0.78 | - | - |
| Loss (Gain) From Sale of Assets | 4.03 | 4.37 | 4.29 | -0.53 | 1.65 | 1.11 |
| Stock-Based Compensation | 423.09 | 343.46 | - | - | - | - |
| Provision & Write-off of Bad Debts | 20.2 | 20.2 | - | - | - | 3.48 |
| Other Operating Activities | 66.29 | -68.05 | -474.93 | -393.69 | 82.75 | 377.65 |
| Change in Accounts Receivable | -970.2 | 330.46 | -2,164 | 521.31 | -715.29 | -1,481 |
| Change in Inventory | 1,781 | -1,291 | -819.31 | -711.86 | -231.67 | 903.43 |
| Change in Accounts Payable | -1,377 | 93.75 | 288 | 71 | -120.84 | 24.72 |
| Change in Other Net Operating Assets | 119.54 | -657.05 | 75.13 | -916.75 | -321.21 | -390.37 |
| Operating Cash Flow | 6,336 | 4,183 | 1,402 | 3,060 | 3,329 | 2,776 |
| Operating Cash Flow Growth | 135.99% | 198.49% | -54.20% | -8.09% | 19.91% | - |
| Capital Expenditures | -3,249 | -3,145 | -2,900 | -1,889 | -1,558 | -1,158 |
| Sale of Property, Plant & Equipment | 47.88 | 22.75 | 6.91 | 0.7 | 0.55 | 313.52 |
| Sale (Purchase) of Intangibles | -1.4 | -1.4 | -8.55 | -56.17 | -31.39 | -39.17 |
| Investment in Securities | -702.48 | 385.54 | 274.07 | -2,262 | -637.06 | -1,105 |
| Other Investing Activities | 1,533 | 1,217 | 413.38 | 446.62 | 171.48 | 28.12 |
| Investing Cash Flow | -2,372 | -1,521 | -2,215 | -3,760 | -2,055 | -1,960 |
| Short-Term Debt Issued | - | - | 919.91 | - | - | 157.21 |
| Long-Term Debt Issued | - | - | 154.7 | 902.9 | - | - |
| Total Debt Issued | 71.39 | - | 1,075 | 902.9 | - | 157.21 |
| Short-Term Debt Repaid | - | -589.41 | - | -7.16 | -506.97 | - |
| Long-Term Debt Repaid | - | -648.66 | - | - | -138.23 | -755.75 |
| Total Debt Repaid | -322.12 | -1,238 | - | -7.16 | -645.2 | -755.75 |
| Net Debt Issued (Repaid) | -250.73 | -1,238 | 1,075 | 895.74 | -645.2 | -598.54 |
| Issuance of Common Stock | 255.19 | - | - | - | 2,475 | 75.94 |
| Repurchase of Common Stock | - | - | -1,831 | - | - | - |
| Preferred Dividends Paid | - | - | - | - | -0.01 | -0.01 |
| Dividends Paid | - | - | - | - | -0.01 | -0.01 |
| Other Financing Activities | -394.5 | -97.92 | -15.19 | -256 | -23.03 | -110.04 |
| Financing Cash Flow | -390.05 | -1,336 | -771.81 | 639.74 | 1,807 | -632.65 |
| Miscellaneous Cash Flow Adjustments | - | - | - | 0.01 | - | 0 |
| Net Cash Flow | 3,573 | 1,326 | -1,585 | -60.56 | 3,081 | 183.4 |
| Free Cash Flow | 3,087 | 1,038 | -1,499 | 1,171 | 1,771 | 1,618 |
| Free Cash Flow Growth | 4370.17% | - | - | -33.91% | 9.44% | - |
| Free Cash Flow Margin | 14.86% | 5.61% | -10.55% | 11.06% | 14.27% | 14.64% |
| Free Cash Flow Per Share | 5.51 | 1.85 | -2.64 | 2.05 | 3.10 | 2.96 |
| Cash Interest Paid | 70.58 | 96.73 | 95.36 | 66.85 | 100.86 | 158.15 |
| Cash Income Tax Paid | 1,760 | 1,590 | 1,200 | 1,150 | 1,230 | 710 |
| Levered Free Cash Flow | 1,564 | 512.86 | -2,186 | 305.5 | 963.49 | - |
| Unlevered Free Cash Flow | 1,610 | 574.68 | -2,129 | 355.97 | 1,036 | - |
| Change in Working Capital | -446.54 | -1,524 | -2,620 | -1,036 | -1,389 | -943.58 |
Source: S&P Capital IQ. Standard template. Financial Sources.